ArticleESMO gastrointestinal oncology2026
Neoadjuvant immunotherapy followed by surgery versus non-operative management in dMMR/MSI gastroesophageal adenocarcinomas: a case series and review of the literature.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Deficient mismatch repair (dMMR)/microsatellite instable (MSI) gastric adenocarcinomas and gastroesophageal junction adenocarcinomas (GEAs) constitute a biologically distinct subgroup characterized by high immunogenicity and limited benefit from fluoropyrimidine-based chemotherapy. Recent phase II trials, such as NEONIPIGA and INFINITY, have demonstrated unprecedented pathological complete response (pCR) rates with neoadjuvant immune checkpoint blockade, raising the question of whether chemotherapy and surgery could be safely omitted in this population. Material and methods: We retrospectively analyzed all consecutive patients with localized dMMR/MSI GEA treated with neoadjuvant immunotherapy between January 2024 and July 2025 at Paoli-Calmettes Institute (Marseille, France). Clinical, endoscopic, radiologic, and pathological data were prospectively collected and retrospectively reviewed. Pathologically documented response was assessed on surgical specimens when available, and clinical complete response (cCR) was defined by the absence of detectable disease on endoscopy or imaging. Results: Ten patients were included in this retrospective review (median age 70.5 years; six males, four females). Nine of them received neoadjuvant dual immunotherapy, and one received chemoimmunotherapy. Six patients underwent surgery, four achieving pCR; one patient achieved partial regression (TRG1), and one TRG2. Four patients were managed non-operatively with two obtaining complete clinical response, and all ultimately achieved cCR following individualized treatment continuation. After a median follow-up of 19.5 months (range 10-22), all patients were alive and disease-free. Conclusions: These preliminary real-world data suggest that neoadjuvant immunotherapy may be safe and feasible in selected patients with localized dMMR/MSI GEA, and that non-operative management warrants further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.